Adding Lenvatinib Plus Pembrolizumab to TACE Improves Survival in Intermediate-Stage Hepatocellular Cancer
Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, LEAP-012 study finds.
Read More